Somatic 9p24.1 copy number alterations predicted the degree to which HPV-negative advanced squamous head and neck cancers benefitted from Keytruda and Opdivo.
Studies at ESMO showed the importance of repeat biomarker testing to guide treatment after resistance to AstraZeneca's Tagrisso, but tissue-based testing remains a hindrance.
In new guidelines, an expert panel recommended IHC and PCR for certain cancer types and pointed out knowledge gaps supporting NGS in other settings.
The firm envisions marketing the 53-gene signature with its existing MammaPrint and BluePrint tests as a comprehensive platform for breast cancer treatment selection.
The test is first available to employees over age 50 covered under Intermountain's SelectHealth, but the health system has a bigger five-year plan.
At AACR, researchers described how pediatric ALL patients who don't respond to anti-CD19 CAR T-cell therapy have cancers with a unique, stem cell-like epigenome.
The Israeli firm's ENLIGHT test uses transcriptome sequencing plus functional drug interaction data to match more patients to drugs compared to current methods.
Oncologists argued for and against comprehensive NGS at the point of diagnosis but agreed on the need to address quality and cost barriers first.
Through its real-world evidence registry, the firm hopes to further validate its NSCLC recurrence risk test as a tool for guiding adjuvant treatment.
The OlympiA trial showed a disease-free survival benefit with adjuvant PARP inhibitor therapy for early-stage, BRCA1/2-mutated, HER2-negative breast cancer patients.